GlyCosmos Glycolipids
Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
| Database | Last Updated |
|---|---|
| ChEBI | February 3, 2022 |
| KEGG | February 3, 2022 |
| LIPID MAPS Structure Database | February 3, 2022 |
| LipidBank | February 3, 2022 |
| PubChem | February 3, 2022 |
| Main Class | Sub Class | LM ID | Common Name ▼ | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass | Formula |
|---|---|---|---|---|---|---|---|---|---|
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I B antigen(d18:1/22:0)
|
1618.954578
|
C78H142N2O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I B antigen(d18:1/20:0)
|
1590.923278
|
C76H138N2O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I B antigen(d18:1/18:0)
|
1562.891978
|
C74H134N2O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I B antigen(d18:1/16:0)
|
1534.860678
|
C72H130N2O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I B antigen
|
GSG1171
|
||||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I A antigen(d18:1/26:1(17Z))
|
1714.028077
|
C84H151N3O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I A antigen(d18:1/26:0)
|
1716.043727
|
C84H153N3O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I A antigen(d18:1/24:1(15Z))
|
1685.996777
|
C82H147N3O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I A antigen(d18:1/24:0)
|
1688.012427
|
C82H149N3O32
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
type I A antigen(d18:1/22:0)
|
1659.981127
|
C80H145N3O32
|
Displaying entries 121 - 130 of 6008 in total
To see the latest features, please visit our beta site.
International Collaboration
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Acknowledgements
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
